Publications by authors named "T Lesimple"
Background: Immune checkpoint inhibitors (ICIs) have demonstrated their efficacy with a 7.5-year overall survival (OS) close to 50% for advanced stages. The design of clinical trials provides for treatment until progression or toxicity, or for a maximum duration of two years.
View Article and Find Full Text PDFBackground: The Checkmate 067 randomized controlled trial, published in 2015, demonstrated improved progression-free survival and numerically, although not statistically, superior overall survival for ipilimumab + nivolumab. The objective of this study was to compare the efficacy and safety of nivolumab to ipilimumab + nivolumab as first-line treatment for metastatic melanoma in a real-world setting.
Methods: Patients were prospectively included in the French Melbase cohort from 2013 to 2022.
Article Synopsis
- The study investigates the effects of continuing immune checkpoint inhibition (ICI) treatment in patients with metastatic melanoma who experience disease progression, using data from 120 patients.
- It finds that patients who continued ICI treatment had a median overall survival (OS) of 4.2 months, significantly longer than the 1.3 months for those who stopped treatment after progression.
- Despite the survival benefits, the study noted increased hospitalizations and treatments at the end of life in patients continuing ICI, highlighting the need for balanced palliative care.
Background: The 5-year results of this trial showed that adjuvant therapy with dabrafenib plus trametinib resulted in longer relapse-free survival and distant metastasis-free survival than placebo among patients with V600-mutated stage III melanoma. Longer-term data were needed, including data regarding overall survival.
Methods: We randomly assigned 870 patients with resected stage III melanoma with V600 mutations to receive 12 months of dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) or two matched placebos.